Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identification of novel blood-borne soluble binding partners of factor H-related proteins

ABSTRACT: The deposition of circulating complement factor H-related (FHR) proteins in tissues around the body has been implicated in a series of complement-mediated diseases. However, the array of blood-borne binding partners with which they interact remains unclear. Here, we identify novel blood-borne binding partners of FHR proteins using untargeted immunoprecipitation and mass spectrometry. We uncover direct interactions between FHRs and soluble immune mediators including complement C4, cathepsin G (CTSG), mannose-binding lectin 2 (MBL2), platelet basic protein (PPBP), and fibrinogen-like protein 1 (FGL1). Functional assays show that FHR-1 and FHR-2 attenuate CTSG-mediated C3b degradation, while FHR-5 and FHL-1 appear to affect lectin pathway activation via MBL2 binding. These interactions suggest that FHRs perhaps confer activity not only through surface competition with factor H, but also via selective engagement with circulating ligands. Our findings expand the known FHR interactome and provide mechanistic insight into their accumulation at inflammatory sites within the ECM (extracellular matrix). This work reveals potential new avenues for understanding FHR biology and targeting complement dysregulation in disease.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood

SUBMITTER: Tina Beyer

LAB HEAD: Prof. Dr. Simon Clark

PROVIDER: PXD072296 | Pride | 2026-03-30

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	TBE4078-S02-A-TJ1-1.raw	Raw
	TBE4078-S04-A-TJ1-2.raw	Raw
	TBE4078-S06-A-TJ1-3.raw	Raw
	TBE4078-S08-A-TJ1-4.raw	Raw
	TBE4078-S10-A-TJ1-5.raw	Raw

Items per page:

1 - 5 of 50

Publications

Identification of novel blood-borne soluble binding partners of factor H-related proteins.

Tang Jiaqi J Woerz Franziska F Beyer Tina T Boldt Karsten K Rathi Sonika S Zhao Shiying S Wolfram Lasse L Ueffing Marius M Clark Simon J SJ

Scientific reports 20260322 1

PMID: 41866380

Similar Datasets

Protein Microarray Analysis of Antibody Responses of Experimentally Infected Dogs to Borrelia burgdorferi Antigens OspC

Project description:Lyme borreliosis (LB) is a tick-borne infection caused by Borrelia burgdorferi. Dogs are at high risk of exposure to ticks and tick-borne pathogens, including B. burgdorferi. Immunodiagnostic assays are usually based on whole-cell preparations of B. burgdorferi as substrate and, consequently, interpretation of results is confounded by antibody cross-reactivity between borrelial antigens and other bacterial species, as well as the anti-LB vaccination status of the dog. For this study, we examined sera from 33 dogs that were experimentally infected with B. burgdorferi through tick bite. These sera were compared with sera from uninfected dogs in their reactivities to 72 different recombinant B. burgdorferi antigens and 24 OspC protein types on a protein microarray. Amongst antigens frequently recognized by infected dogs were several known to be immunogens for humans, such as Decorin-binding protein A (BBA25), BBA64, fibronectin-binding protein (BBK32), VlsE, Erp and Bdr, CRASP proteins, OspC proteins and some flagellar antigens. Of special interest were the novel antigens BBB14 and BB0844, both hypothetical lipoproteins about which very little is currently known, and that were frequently and strongly recognized by infected dog sera. The antibody response of B. burgdorferi-infected dogs presents both similarities and differences from human counterparts, and both can be important for improvement of canine LB diagnosis and vaccine development. Antibody profiling was performed on sera from dogs experimentally-infected with B. burgdorferi and unexposed controls against antigens of B. burgdorferi. Thirty-three serum samples from experimental infections, and 5 unexposed controls were probed on a protein microarray displaying 24 OspC proteins of B. burgdorferi .

2013-08-22 | E-GEOD-50075 | biostudies-arrayexpress

Protein Microarray Analysis of Antibody Responses of Experimentally Infected Dogs to Borrelia burgdorferi Antigens

Project description:Lyme borreliosis (LB) is a tick-borne infection caused by Borrelia burgdorferi. Dogs are at high risk of exposure to ticks and tick-borne pathogens, including B. burgdorferi. Immunodiagnostic assays are usually based on whole-cell preparations of B. burgdorferi as substrate and, consequently, interpretation of results is confounded by antibody cross-reactivity between borrelial antigens and other bacterial species, as well as the anti-LB vaccination status of the dog. For this study, we examined sera from 33 dogs that were experimentally infected with B. burgdorferi through tick bite. These sera were compared with sera from uninfected dogs in their reactivities to 72 different recombinant B. burgdorferi polypeptides on a protein microarray. Amongst antigens frequently recognized by infected dogs were several known to be immunogens for humans, such as Decorin-binding protein A (BBA25), BBA64, fibronectin-binding protein (BBK32), VlsE, Erp and Bdr, CRASP proteins, OspC proteins and some flagellar antigens. Of special interest were the novel antigens BBB14 and BB0844, both hypothetical lipoproteins about which very little is currently known, and that were frequently and strongly recognized by infected dog sera. The antibody response of B. burgdorferi-infected dogs presents both similarities and differences from human counterparts, and both can be important for improvement of canine LB diagnosis and vaccine development. Antibody profiling was performed on sera from dogs experimentally-infected with B. burgdorferi and unexposed controls against antigens of B. burgdorferi. Thirty-three serum samples from experimental infections, and 6 unexposed controls were probed on a protein microarray displaying 72 unique proteins of B. burgdorferi .

2013-08-22 | E-GEOD-50074 | biostudies-arrayexpress

Structural insights into Siglec-15 reveal glycosylation dependency for its interaction with T cells through integrin CD11b

Project description:Sialic acid-binding Ig-like lectin 15 (Siglec-15) is emerging as an immune modulator and target for cancer immunotherapy. However, limited knowledge regarding its mechanism of action and structure, or its binding partners with T cells, restrains the development of drug candidates that could unleash its full therapeutic potential. Here, we determine the crystal structure of Siglec-15 and delineate its binding epitope by co-crystallization with an anti-Siglec-15 blocking antibody. Saturation transfer-difference nuclear magnetic resonance (STD-NMR) spectroscopy assisted with molecular dynamics simulations reveals the binding mode of Siglec-15 to (2,3)- and 2,6)- linked sialic acids and to the cancer-associated sialyl-Tn (STn) glycoform. Binding of Siglec-15 to T cells, which lack STn expression, depends on the presence of (2,3)- and 2,6)- linked sialoglycans. We identify the leukocyte integrin CD11b as a binding partner of Siglec-15 on human T cells. Collectively, these data provide an integrative understanding of the structural features of Siglec-15 and underscore glycosylation as an additional layer of control of T cell responses.

2023-07-20 | PXD042009 | Pride

Expression data of microRNAs captured by OAA from plasma of NSCLC patients treated with nivolumab

Project description:Background: Predictive biomarkers for immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC) are limited. High-mannose glycans, enriched in tumors, can be selectively captured using OAA1 (recombinant OAA), a novel lectin. This study investigates whether plasma microRNAs (miRNAs) enriched by OAA1 serve as predictive markers of response to anti-PD-1 therapy. Methods: Pre-treatment plasma samples from 48 NSCLC patients treated with nivolumab were processed using OAA1 lectin columns. Levels of circulating miR-320a, miR-320b, and miR-3613-5p , which were identified as resistance associated miRNAs by microarray, were quantified with and without OAA1 enrichment. Associations with therapeutic response and overall survival were analyzed. Results: The three miRNAs were significantly upregulated in patients with stable or progressive disease compared to partial responders, but only after OAA1 enrichment. ROC and survival analyses showed improved predictive and prognostic power with OAA1-enriched miRNAs. For example, miR-3613-5p’s AUC improved from 0.837 to 0.897, and its hazard ratio increased from 3.386 to 7.815. Conclusion: OAA1-captured plasma miRNAs are associated with resistance to nivolumab and poor prognosis in NSCLC. This glycan-based enrichment strategy enhances the clinical value of circulating miRNAs and may complement tissue-based ICI biomarkers.

2026-04-01 | GSE310370 | GEO

Long Neural Genes Harbor Recurrent DNA Break Clusters in Neural Stem/Progenitor Cells

Project description:Repair of DNA double-strand breaks (DSBs) by non-homologous end-joining is critical for neural development, and brain cells frequently contain somatic genomic variations that might involve DSB intermediates. We now use an unbiased, high-throughput approach to identify genomic regions harboring recurrent DSBs in primary neural stem/progenitor cells (NSPCs). We identify 27 recurrent DSB clusters (RDCs) and, remarkably, all occur within gene bodies. Most of these NSPC RDCs were detected only upon mild, aphidicolin-induced replication stress, providing a nucleotide-resolution view of replication-associated genomic fragile sites. The vast majority of RDCs occur in long, transcribed, and late-replicating genes. Moreover, almost 90% of identified RDC-containing genes are involved in synapse function and/or neural cell adhesion, with a substantial fraction also implicated in tumor suppression and/or mental disorders. Our characterization of NSPC RDCs reveals a basis of gene fragility and suggests potential impacts of DNA breaks on neurodevelopment and neural functions. We performed high-throughput, genome-wide, translocation sequencing (HTGTS) and GRO-seq in primary mouse neural stem/progenitor cells of the indicated genotypes.

2016-02-15 | E-GEOD-74356 | biostudies-arrayexpress

Danio rerio

Project description:Complement lectin pathway restrain mycobacterial infection in vivo by inhibiting ferroptosis (PRJCA051147)

| PRJDB41663 | ENA

Project description:Role of the complement lectin pathway activation in COVID-19 disease severity

| PRJEB60441 | ENA

TFMI-3 plasma pull-down - MASP-3 is the exclusive pro-factor D activator in resting blood: the lectin and the alternative complement pathways are fundamentally linked

Project description:MASP-3 is the third protease of the lectin pathway of the complement system, but its biological function has remained obscure. To elucidate its role in complement activation, we developed a specific MASP-3 inhibitor (named TFMI-3). In this work we unambiguously demonstrate that MASP-3 acts as the exclusive pro-FD activator in resting blood.

2016-08-24 | PXD003666 | Pride

Lipopolysaccharide (LPS) effect on ficolin deficient spleen

Project description:Analysis of spleens from ficolin knockout and wildtype mice treated without and with LPS to induce inflammation. Ficolins are pattern recognition molecules that initiate the lectin pathway of complement. Results provide insigt into the molecular basis of the inflammatory response of ficolin knockout mice.

2017-02-22 | GSE95125 | GEO

Ptprf is the conserved receptor for Asprosin’s glucogenic effects in vertebrates

Project description:Asprosin, a fasting-induced glucogenic hormone, plays a crucial role in maintaining glucose homeostasis; however, its receptor remains elusive. This study identifies protein tyrosine phosphatase receptor F (Ptprf) as the receptor mediating Asprosin's metabolic functions. Using zebrafish models, we demonstrate the evolutionary conservation of Asprosin's role in glucose metabolism. Through binding assays, we determined Ptprf as Asprosin's interacting receptor in zebrafish liver. Zebrafish possess two Ptprf paralogs (Ptprfa/b), both hepatically expressed and binding Asprosin with high affinity. Genetic ablation of ptprfa/b reduced basal glucose levels and eliminated Asprosin-induced hyperglycemia. Conversely, overexpression of soluble Ptprf ligand-binding domains neutralized Asprosin's glucogenic effects. These findings were validated in mammals: Asprosin binds PTPRF in mice and humans, and Ptprf knockout mice showed blunted response to Asprosin. Our results establish Ptprf as an evolutionarily conserved Asprosin receptor across vertebrates, providing mechanistic insights for developing therapies targeting this pathway for diabetes and obesity.

2026-01-12 | PXD072402 | Pride